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Abstract
Three types of nanoparticle formulation from biodegradable PLGA-TPGS random copolymer were developed in this
research for oral administration of anticancer drugs, which include DMAB-modified PLGA nanoparticles, unmodified
PLGA-TPGS nanoparticles and DMAB-modified PLGA-TPGS nanoparticles. Firstly, the PLGA-TPGS random copolymer
was synthesized and characterized. DMAB was used to increase retention time at the cell surface, thus increasing the
chances of particle uptake and improving oral drug bioavailability. Nanoparticles were found to be of spherical shape
with an average particle diameter of around 250 nm. The surface charge of PLGA-TPGS nanoparticles was changed
to positive after DMAB modification. The results also showed that the DMAB-modified PLGA-TPGS nanoparticles have
significantly higher level of the cellular uptake than that of DMAB-modified PLGA nanoparticles and unmodified
PLGA-TPGS nanoparticles. In vitro, cytotoxicity experiment showed advantages of the DMAB-modified PLGA-TPGS
nanoparticle formulation over commercial Taxotere® in terms of cytotoxicity against MCF-7 cells. In conclusion, oral
chemotherapy by DMAB-modified PLGA-TPGS nanoparticle formulation is an attractive and promising treatment
option for patients.
Introduction
Oncology is one of the few areas of medicine where
most patients are treated intravenously rather than
receiving oral medications. Oral chemotherapy is attrac-
tive because of its convenience and ease of administra-
tion, particularly in a palliative setting. In addition, the
oral route facilitates the use of more chronic treatment
regimens, which result in prolonged exposure to anti-
cancer drugs. However, most anticancer drugs such as
Taxoids (paclitaxel and docetaxel) are not orally bio-
available, i.e., not absorbable in the gastrointestinal (GI)
tract. This is because Taxoids have a very low level of
oral bioavailability at less than 10% [1,2]. The low sys-
temic exposure of Taxoids after oral drug administration
is, at least in part, due to their high affinity for the mul-
tidrug efflux pump P-glycoprotein (P-gp) [3,4]. P-gp in
the mucosa of the GI tract limits the absorption of the
orally administered Taxoids and mediates their direct
excretion into the gut lumen [3]. In addition, first-pass
elimination by cytochrome P450 (CYP) isoenzymes in
the liver and/or gut wall may also contribute to the low
oral bioavailability of Taxoids [5,6]. Possible solutions
for oral delivery of Taxoids and other anticancer drugs
are currently under extensive investigation [2]. The gen-
eral idea is to apply P-gp/P450 inhibitors such as cyclos-
porine to suppress the elimination process [7,8].
However, P-gp/P450 inhibitors may suppress the body’s
immune system and thus cause severe medical compli-
cations. Polymeric nanoparticles are of special interest
from the pharmaceutical point of view. Polymeric nano-
particles could escape from the recognition of P-gp and
thus bear the most potential to enhance the oral bio-
availability of drugs that are otherwise poorly absorbed
when administered orally [9-11]. Their submicron size
and their large specific surface area favor their absorp-
tion compared to larger carrier. The nanoparticles could
also shield incorporated drug molecules from the gastro-
intestinal tract (GIT) degradation as well as gut wall
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metabolism. In addition, the nanoparticles could bypass
the liver and prevent the first-pass metabolism of the
incorporated drug [12]. It has been fully accepted that
nanoparticle surface properties are of outmost impor-
tance for their uptake by intestinal epithelial cells.
Hence, many strategies have been developed to improve
mucosal absorption of nanoparticles, either by modifying
their surface properties or by coupling a targeting mole-
cular at their surface [13]. In the present study, we
proposed a novel nanoparticle formulation, i.e., biode-
gradable PLGA-TPGS nanoparticles modified with a
cationic surfactant, didodecyldimethylammonium bro-
mide (DMAB) (named DMAB/PLGA-TPGS NPs herein-
after), for oral chemotherapy using docetaxel as a
therapeutic drug due to its excellent therapeutic effects
against a wide spectrum of cancers and its commercial
success as one of the top-selling anticancer agents.
Reports on the positive surface charge of DMAB pro-
vided the incentive to aid drug adsorption and delivery,
since it is expected to ensure better interaction with the
negatively charged cell membrane [14-16]. This can
result in increased retention time at the cell surface,
thus increasing the chances of particle uptake and
improving oral drug bioavailability [17]. DMAB is cap-
able of producing small and highly stable nanoparticles
at 1% w/v concentration [18]. Due to the charged sur-
face, the particle agglomeration is impeded. Thus, in
this research, DMAB was absorbed on the nanoparticle
surface by electrostatic attraction between positive and
negative charges. In our design, the FDA-approved bio-
degradable polymer PLGA was employed to maintain
the mechanical strength of the copolymer. D-a-toco-
pheryl polyethylene glycol 1,000 succinate (TPGS) is a
water-soluble derivative of natural vitamin E, which is
formed by esterification of vitamin E succinate with
polyethylene glycol (PEG) 1,000. TPGS could improve
drug permeability through cell membranes by inhibiting
P-glycoprotein, and thus enhance absorption of drugs
and reduce P-glycoprotein-mediated multidrug resis-
tance in tumor cells [19-21]. It was found that TPGS
could also effectively inhibit the growth of human lung
carcinoma cells from in vitro cell culture and implanted
in nude mice [22]. The superior anticancer efficacy of
TPGS is associated with its increasing ability to induce
apoptosis and not due to its increased cell uptake into
cells [22-24]. Synergistic antitumor effects could be
obtained by the use of combinations of vitamin E iso-
mers or derivatives in the presence of other anticancer
agents [23]. In addition, TPGS-emulsified nanoparticles
have been shown higher drug encapsulation and cellular
uptake, longer half-life and higher therapeutic effects of
the formulated drug than those emulsified by poly (vinyl
alcohol) (PVA), a widely used emulsifier in nanoparticle
technology [21]. We were thus inspired to synthesize a
novel biodegradable poly(lactide-co-glycolide)-D-a-toco-
pheryl polyethylene glycol 1,000 succinate (PLGA-
TPGS) random copolymer for nanoparticle formulation




with purity above 99% and didodecyldimethylammonium
bromide (DMAB) were purchased from Sigma–Aldrich
(St. Louis, MO, USA). D-a-tocopheryl polyethylene glycol
1,000 succinate (TPGS, C33O5H54 (CH2CH2O)23), PLGA
(50:50, MW 50,000), glycolide (1,4-Dioxane-2,5-dione,
C4H4O4), stannous octoate (Sn(OOCC7H15)2) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) were also supplied from Sigma–Aldrich (St. Louis,
MO, USA). Docetaxel of purity 99.8% was purchased from
Shanghai Jinhe Bio-Technology Co. Ltd (Shanghai, China).
Acetonitrile and methanol were purchased from EM
Science (ChromAR, HPLC grade, Mallinckrodt Baker,
USA). All other chemicals used were of the highest quality
commercially available. Ultrahigh pure water produced by
Boon Environmental Tech. Industry Co., Ltd (Tianjin,
China) was utilized throughout all experiments.
Synthesis and Characterization of PLGA-TPGS
Random Copolymers
PLGA-TPGS random copolymers were synthesized from
lactide, glycolide and TPGS in the presence of stannous
octoate as a catalyst via ring opening polymerization
[21]. In brief, weighted amounts of lactide, glycolide,
TPGS and 0.5 wt% stannous octoate (in distilled
toluene) were added in a flask. The mixture was heated
to 145°C and allowed to react for 12 h. Synthesis was
carried out under an oxygen- and moisture-free envir-
onment. The product was dissolved in DCM and then
precipitated in excess cold methanol to remove
unreacted lactide monomers and TPGS. The final pro-
duct was collected by filtration and vacuum dried at 45°C
for 2 days. The TPGS content and number-averaged
molecular weight of the copolymer were determined by
1H NMR in CDCl3 at 300 Hz (Bruker ACF300). The
weight-averaged molecular weight and molecular weight
distribution were determined by gel permeation chroma-
tography (Waters GPC analysis system with RI-G1362A
refractive index detector, Waters, Milford, USA).
Preparation of DMAB-Modified Nanoparticles
Nanoparticles were fabricated by a solvent extraction/
evaporation method with slight modifications [25,26].
Briefly, a given amount of docetaxel and 100 mg PLGA-
TPGS copolymer were dissolved in 8 ml dichloro-
methane (DCM). The formed solution was poured into
120 ml of 0.03% (w/v) TPGS solution under gentle
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stirring. The mixture was sonicated for 120 s at 25 W
output to form O/W emulsion. The emulsion was then
evaporated overnight under reduced pressure to remove
DCM. The particle suspension was centrifuged at 22,000
rpm for 20 min, and then washed three times to remove
TPGS and unencapsulated drug. The resulted particles
were resuspended in 10 ml DI water and freeze-dried.
The surface modification of the PLGA-TPGS nanoparti-
cles was carried out by a method described previously
[14]. DMAB was dissolved in DI water at a concentra-
tion of 0.5 mg/ml. Preweighed nanoparticles were sus-
pended in this solution at a concentration of 9.5 mg/ml
by sonication at 25 W power output for 60 s over an ice
bath, and then were collected by ultracentrifugation. In
addition, the fluorescent coumarin-6-loaded nanoparti-
cles were prepared in the same way, except 0.1% (w/v)
coumarin-6 was encapsulated instead of docetaxel.
DMAB-modified PLGA nanoparticles were prepared by
the same method.
Characterization of Nanoparticles
Size Analysis and Surface Charge
Size and size distribution of nanoparticles were deter-
mined by Dynamic Light Scattering (Zetasizer Nano
ZS90, Malvern Instruments LTD., Malvern, UK). The
particles (about 2 mg) were suspended in deionized water
before measurement. Zeta potential of the nanoparticles
was measured by Laser Doppler Anemometry (LDA;
Zetasizer Nano ZS90, Malvern Instruments LTD., Mal-
vern, UK). The measurement was performed triplicate.
Surface Morphology
The particle morphologies were examined by a field
emission scanning electron microscopy (FESEM), using a
JEOL JSM-6700F system operated at a 5.0 kV accelerat-
ing voltage. To prepare samples for FESEM, the particles
were fixed on the stub by a double-sided sticky tape and
then coated with platinum layer by JFC-1,300 automatic
fine platinum coater (JEOL, Tokyo, Japan) for 40 s.
Drug Content and Entrapment Efficiency
Drug loading content and entrapment efficiency (EE) of
the nanoparticles were determined by HPLC (LC 1200,
Agilent Technologies, Santa Clara, CA) according to
previously published methods [13,14]. Briefly, 5 mg
nanoparticles were dissolved in 1 ml DCM under vigor-
ous vortexing. This solution was transferred to 5 ml of
mobile phase consisting of deionized water and acetoni-
trile (50:50, v/v). A nitrogen stream was introduced to
evaporate the DCM for about 15 min, and then a clear
solution was obtained for HPLC analysis. A reverse-
phase Inertsil® C-18 column (150 mm × 4.6 mm, pore
size 5 mm, GL science Inc, Tokyo, Japan) was used. The
flow rate of mobile phase was 1 ml/min. The column
effluent was detected at 227 nm with a UV/VIS detec-
tor. The drug EE was defined as the ratio between the
amount of docetaxel encapsulated in the nanoparticles
and that added in the process. Experiments were
performed in triplicate, and results are expressed as
mean ± standard deviation (SD).
In Vitro Drug Release
Fifteen milli-gram docetaxel-loaded nanoparticles were
dispersed in 5 ml release medium (phosphate buffer solu-
tion of pH 7.4 containing 0.1% w/v Tween 80) to form a
suspension. Tween 80 was used to increase the solubility
of docetaxel in the buffer solution and avoid the binding
of docetaxel to the tube wall. The suspension was trans-
ferred into a Regenerated Cellulose Dialysis Membrane
(Spectra/Por 6, MWCO = 1,000, Spectrum, Houston,
TX, USA). Then, the closed bag was put into a centrifuge
tube and immersed in 15 ml release medium. The tube
was put in an orbital water bath shaking at 120 rpm at
37.0°C. Ten milliliter of solutions were periodically
removed for analysis and replaced with fresh medium.
The collected samples were extracted with 2 ml DCM
and reconstituted in 5 ml mobile phase. A nitrogen
stream was introduced to evaporate the DCM. The analy-
sis procedure was the same as for the measurement of
encapsulation efficiency.
Cellular Uptake of Nanoparticles
Caco-2 cells of passage 30–35 (American Type Culture
Collection, VA) were used in this study to simulate the
GI barrier for oral chemotherapy, which were grown in
25-cm2 tissue culture flasks maintained at 37°C in a
humidified environment of 5% CO2. The medium,
Dubelco’s modified essential medium (DMEM, Sigma
D1152) supplemented with 20% fetal bovine serum,
100 U/ml penicillin and 100 (g/ml streptomycin (Sigma)
was freshened every 3 days. After 90% confluence, the
cells were collected by 0.25% of Trypsin–EDTA solution
(Sigma) and cultured in 96-well black plate (Costa®,
Corning Incorporated) at a density of 1.3 × 104 cells/
well; after the cells reached confluence, the cells were
equilibrated with HBSS at 37°C for 1 h and then incu-
bated with coumarin-6-loaded nanoparticle suspension.
The nanoparticles were dispersed in the medium at con-
centration of 100, 250 and 500 (g/ml). The wells with
nanoparticles were incubated at 37°C for 2 h. After
incubation, the suspension was removed and the wells
were washed three times with 50 μl cold PBS to elimi-
nate traces of nanoparticles left in the wells. After that,
50 μl of 0.5% Triton X-100 in 0.2 N NaOH was intro-
duced into each sample wells to lyse the cells. The
fluorescence intensity of each sample well was measured
by microplate reader (GENios, Tecan, Switzerland) with
excitation wave length at 430 nm and emission wave-
length at 485 nm. Cell uptake efficiency was expressed
as the percentage of cells associated fluorescence versus
the fluorescence present in the feed solution. Culture of
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human breast adenocarcinoma cell line MCF-7 cells
(passage 30–35, American Type Culture Collection) and
their uptake of the coumarin-6-loaded nanoparticles
were performed in the same way.
Caco-2 cells were re-seeded in the chambered cover
glass system (LABTEK®, Nagle Nunc, IL). After the cells
were incubated with 250 μg/ml coumarin-6-loaded
DMAB-modified PLGA-TPGS nanoparticle suspension
at 37°C for 2 h, the cells were rinsed with cold PBS for
three times and then fixed by ethanol for 20 min. The
cells were further washed twice with PBS, and the nuclei
were counterstained with propidium iodide (PI) for
30 min. The cell monolayer was washed twice with PBS
and mounted in Dako® fluorescent mounting medium
(Dako, CA) to be observed by confocal laser scanning
microscope (CLSM) (Zeiss LSM 410) with an imaging
software, Fluoview FV500.
In Vitro Cell Viability
MCF-7 cells were seeded in 96-well plates at the density
of 5,000 viable cells per well and incubated 24 h to allow
cell attachment. The cells were incubated with docetaxel-
loaded PLGA-TPGS nanoparticle suspension, DMAB-
modified PLGA-TPGS nanoparticle suspension and
commercial Taxotere® at 0.25, 2.5, 12.5 and 25 μg/ml
equivalent docetaxel concentrations and drug-free
DMAB-modified PLGA-TPGS nanoparticle suspension
with the same amount of nanoparticles for 24, 48 and
72 h, respectively. At determined time, the formulations
were replaced with DMEM containing MTT (5 mg/ml)
and cells were then incubated for additional 4 h. MTT
was aspirated off and DMSO was added to dissolve the
formazan crystals. Absorbance was measured at 570 nm
using a microplate reader (Bio-Rad Model 680, UK).
Untreated cells were taken as control with 100% viability,
and cells without addition of MTT were used as blank to
calibrate the spectrophotometer to zero absorbance. IC50,
the drug concentration at which inhibition of 50% cell
growth was observed, in comparison with that of the
control sample, was calculated by curve fitting of the cell
viability data. Experiments were performed in triplicate
and results are expressed as mean ± SD.
Statistical Methodology
The results were expressed as mean ± SD. The signifi-
cance of differences was assessed using Student’s t-test
and was termed significance when P < 0.05.
Results and Discussions
Characterization of PLGA-TPGS Random Copolymer
The chemical structure of the PLGA-TPGS random copo-
lymer synthesized in our research can be found from our
earlier work [21]. The Characterization of 1H NMR and
GPC is tabulated in Table 1. The weight-averaged and
number-averaged molecular weight of the PLGA-TPGS
random copolymer with PLGA:TPGS = 90:10 were deter-
mined to be 28,530 and 21,944, respectively, with polydis-
persity of 1.30. As shown in Figure 1, the copolymer was
successfully synthesized at the characteristic peak of 5.2
and 1.69 ppm for PLA, 4.82 ppm for PGA and at that of
3.65 ppm for TPGS, respectively.
Characterization of Drug-Loaded Nanoparticles
Size, Zeta Potential and Drug Entrapment Efficiency
The size and size distribution of the 5% DMAB-modi-
fied PLGA nanoparticles(ANP), unmodified PLGA-
TPGS nanoparticles(BNP), 5% DMAB-modified PLGA-
TPGS nanoparticles(CNP) and 20% DMAB-modified
PLGA-TPGS nanoparticles(DNP) prepared in this
research are shown in Table 2. The particle size is a key
parameter used to determine the cellular uptake of the
nanoparticles. The permeability of the particles through
the intestinal mucosa decreases with increasing the par-
ticle size reaching a cut-off at around 500 nm [27,28].
The prepared nanoparticles were of 200–300 nm dia-
meter, which is in the size range favoring the intestinal
uptake of the nanoparticles [2]. The results also showed
that the addition of DMAB resulted in a slight decrease
in particle size. Zeta potential analysis confirmed that
surface modification with 5% DMAB changed the
PLGA-TPGS nanoparticles from a negative surface












15.00 10.44 1.30 28,530 21,944
aCalculated by 1H NMR
bCalculated by GPC
Figure 1 Typical 1H-NMR spectra of PLGA-TPGS random
copolymer.
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charge of -21.87 to a significantly positive charge of
+32.23. Literature suggests that positive surface charge
enhances mucosal uptake due to anionic nature of
mucous layer [18]. It has been also reported that the
efficiency of arterial uptake of nanoparticles could be
improved by at least sevenfold after DMAB modification
of nanoparticles [29].
As the drug entrapment efficiency (EE) regards, it can be
seen from Table 2 that the 5% DMAB-modified PLGA-
TPGS nanoparticles (CNP) achieved much higher EE than
the 5% DMAB-modified PLGA nanoparticles (ANP).
This might be contributed to the self-emulsification effect
of the PLGA-TPGS copolymer [2,21].
Surface Morphology
Surface morphology of the 5% DMAB-modified PLGA-
TPGS nanoparticles (CNP) was examined by FESEM.
Figure 2 shows the FESEM images of 5% DMAB-
modified PLGA-TPGS nanoparticles (CNP). The FESEM
image further confirmed the particle size detected from
the DLS. The morphology of the nanoparticles formed
was recorded as smooth and spherical in shape.
In vitro Drug Release
The in vitro drug release profiles of the 5% DMAB-modi-
fied PLGA nanoparticles (ANP),unmodified PLGA-TPGS
nanoparticles (BNP) and 5% DMAB-modified PLGA-
TPGS nanoparticles (CNP) in the first 28 days are shown
in Figure 3. The drug release from the 5% DMAB-modi-
fied PLGA-TPGS nanoparticles (CNP) was found to be
36.98% and 63.22% of the encapsulated drug in the first
5 days and after 28 days, respectively, which was much
faster than the 5% DMAB-modified PLGA nanoparticles
(ANP), which is only 15.99% and 29.39%, respectively, in
the same periods. The faster drug release of 5% DMAB-
modified PLGA-TPGS nanoparticles (CNP) may be
attributed to the lower molecular weight and the higher
hydrophilicity of PLGA-TPGS copolymer in comparison
with the PLGA nanoparticles. It causes the copolymer to
swell and to degrade faster, thus promoting the drug
release from the nanoparticles. It can also be seen from
Figure 3 that drug release from the 5% DMAB-modified
PLGA-TPGS nanoparticles (CNP) was slightly faster than
that of unmodified PLGA-TPGS nanoparticles (BNP).
Such a phenomenon may be attributed to slightly smaller
particle size of 5% DMAB-modified PLGA-TPGS nano-
particles (CNP). It may be thought that in vitro, drug
release should be evaluated ideally in a release medium
which can better simulate the acidic condition of the gas-
trointestinal fluid. However, this is not an important
issue since the nanoparticles would stay with the GI
track for a few hours only. Drug release in plasma and in
the cancer cells plays a more important role.
Table 2 Effects of DMAB modification on size, entrapment efficiency and zeta potential
Group Polymer Size (nm) PDI Zeta Potential (mV) Drug loading (%) EE (%) DMAB Modification (%)
ANP PLGA 239.82 ± 8.64 0.299 -28.58 ± 4.44 8.93 88.26 5
BNP PLGA-TPGS 253.51 ± 5.38 0.264 -21.87 ± 2.11 9.83 98.27 None
CNP PLGA-TPGS 226.33 ± 3.56 0.251 32.23 ± 3.55 9.62 96.23 5
DNP PLGA-TPGS 219.42 ± 5.24 0.199 34.15 ± 4.28 9.21 92.12 20
PDI polydispersity index, EE drug entrapment efficiency, n = 3
Figure 2 FESEM image of docetaxel-loaded 5% DMAB-modified
PLGA-TPGS nanoparticles.
Figure 3 The in vitro release profile of docetaxel-loaded 5%
DMAB-modified PLGA nanoparticles (ANP), unmodified PLGA-
TPGS nanoparticles (BNP) and 5% DMAB-modified PLGA-TPGS
nanoparticles (CNP).
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Uptake of Coumarin-6-Loaded Nanoparticles
by Caco-2 and MCF-7 Cells
Caco-2 cells are a widely accepted model to predict per-
meability and absorption of compounds in humans [30].
Taxoids have been extensively used to treat metastatic
breast cancer. The fluorescence uptake by the MCF-7
cells could provide a useful model to assess the in vitro
therapeutic effect of the Taxoids in the various formula-
tions for breast cancer treatment [31,32]. The cellular
uptake of coumarin-6-loaded 5% DMAB-modified PLGA
nanoparticles (ANP), unmodified PLGA-TPGS nanopar-
ticles (BNP) and 5% DMAB-modified PLGA-TPGS nano-
particles (CNP) was thus evaluated in this research using
Caco-2 cell line as in vitro model of the GI barrier and
MCF-7 cell line as model cancer cells. The cellular
uptake efficiency of the coumarin-6-loaded nanoparticles
by Caco-2 and MCF-7 cells was assayed upon 2-h incu-
bation, and the results are shown in Figure 4.
It can be observed from Figure 4a that there is an
increasing trend in the Caco-2 cellular uptake which
shows the 5% DMAB-modified PLGA-TPGS nanoparti-
cles (CNP) >5% DMAB-modified PLGA nanoparticles
(ANP) >unmodified PLGA-TPGS nanoparticles (BNP).
Such advantages are particle concentration dependent.
The 5% DMAB-modified PLGA-TPGS nanoparticles
(CNP) resulted in 1.37-, 1.46- and 1.45-fold higher cellu-
lar uptake than that of 5% DMAB-modified PLGA
nanoparticles (ANP), and 1.52-, 1.67- and 1.59-fold
higher cellular uptake than that of unmodified PLGA-
TPGS nanoparticles (BNP) at the incubated particle
concentration of 100, 250 and 500 μg/ml, respectively.
Figure 4b shows that the cellular uptake efficiency of the
coumarin-6-loaded DMAB-modified PLGA-TPGS nano-
particles (CNP) by MCF-7 cells is higher than that of 5%
DMAB-modified PLGA nanoparticles (ANP) and unmodi-
fied PLGA-TPGS nanoparticles (BNP), which is also
found dose-dependent. The 5% DMAB-modified PLGA-
TPGS nanoparticles (CNP) resulted in 1.37-, 1.53- and
1.61-fold higher cellular uptake than that of 5% DMAB-
modified PLGA nanoparticles (ANP), and 1.40-, 1.41- and
1.52-fold higher cellular uptake than that of unmodified
PLGA-TPGS nanoparticles (BNP) at the incubated particle
concentration of 100, 250 and 500 μg/ml, respectively. The
positive surface charge of DMAB provided the incentive to
aid drug delivery, since it is expected to ensure better
interaction with the negatively charged cell membrane
[14-16]. This resulted in increased retention time at the
cell surface, thus increasing the chances of particle uptake
and improving oral drug bioavailability [17].
Figure 5 shows confocal laser scanning microscopy
(CLSM) images of Caco two cells after 2 h incubation
with the coumarin-6-loaded 5% DMAB-modified PLGA-
TPGS nanoparticles at 250 μg/ml nanoparticle concen-
tration, in which, the upper-left image was obtained
from FITC channel (green), the lower-left one was from
propidium iodide (PI) channel (red), the upper-right
image was from transmitted light channel (black and
white), and the lower-right image was the combination
of all the three images. It can be seen from this figure
that the fluorescence of the coumarin-6-loaded 5%
DMAB-modified PLGA-TPGS nanoparticles (green) is
located in the cytoplasm around the nucleus (red,
stained by PI), indicating the nanoparticles has been
internalized into the cells [33].
Cell Viability
Figure 6 shows the viability of MCF-7 cancer cells after
24 (upper), 48 (middle) and 72 (lower) hour cell
culture with docetaxel formulated in the 5% DMAB-
modified PLGA nanoparticles (ANP), unmodified
PLGA-TPGS nanoparticles (BNP) and 5% DMAB-
modified PLGA-TPGS nanoparticles (CNP) respectively
Figure 4 Cellular uptake of coumarin-6-loaded 5% DMAB-
modified PLGA nanoparticles (ANP), unmodified PLGA-TPGS
nanoparticles (BNP) and 5% DMAB-modified PLGA-TPGS
nanoparticles (CNP) by a Caco-2 and b MCF-7 cells after 2-h
incubation.
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in comparison with that of the Taxotere® formulation
at the same 0.025, 0.25, 2.5, 10 and 25 μg/ml docetaxel
dose (n = 6). It can be concluded from this figure that
in general (1) All 3 nanoparticle formulations showed
advantages in decreasing the cancer cell viability (i.e.
increasing the cancer cell mortality) versus the current
clinical dosage form Taxotere® and the 5% DMAB-
modified PLGA-TPGS nanoparticles (CNP) can have
even better effects than unmodified PLGA-TPGS
nanoparticles (BNP). Such advantages of the nanoparti-
cle formulations can be contributed to the effects of
TPGS and DMAB component of the nanoparticles in
enhancing cellular uptake of the nanoparticles. (2) The
advantages in cancer cell viability of the 5% DMAB-
modified PLGA-TPGS nanoparticles (CNP) >the
unmodified PLGA-TPGS nanoparticles (BNP) >the
Taxotere® formulation is dependent on the incubation
time. This may be contributed to the controlled release
manner of the nanoparticle formulation. (3) The
advantages in cancer cell viability of the 5% DMAB-
modified PLGA-TPGS nanoparticles (CNP) >the
unmodified PLGA-TPGS nanoparticles (BNP) >the
Taxotere® formulation is also dependent on the drug
concentration. The higher the drug concentration, the
more significant effects would be obtained.
The advantages in cancer cell viability of the 5%
DMAB-modified PLGA-TPGS nanoparticles (CNP) >the
unmodified PLGA-TPGS nanoparticles (BNP) >the
Taxotere® formulation can be quantitatively analyzed by
IC50, which is defined as the drug concentration at
which 50% of the cells in culture have been killed in a
designated time period. Table 3 gives IC50 of MCF-7
Figure 5 Confocal laser scanning microscopy (CLSM) images of HeLa cells after 2 h incubation with coumarin-6-loaded 5% DMAB-
modified PLGA-TPGS nanoparticles at 37.0°C. The cells were stained by propidium iodide (red) and the coumarin-6-loaded nanoparticles are
green. The cellular uptake is visualized by overlaying images obtained by white light, FITC filter and PI filter: upper-left image from FITC channel;
upper-right image from transmitted light channel; lower-left image from PI channel; lower-right image from combined transmitted light channel, PI
channel and FITC channel.
Chen et al. Nanoscale Res Lett 2011, 6:4
http://www.nanoscalereslett.com/content/6/1/4
Page 7 of 10
cells after 24-, 48-, 72-h incubation with docetaxel for-
mulated in the Taxotere®, 5% DMAB-modified PLGA
nanoparticles (ANP), unmodified PLGA-TPGS nanopar-
ticles (BNP) and 5% DMAB-modified PLGA-TPGS
nanoparticles (CNP), respectively, which are obtained
from Figure 6. The results showed that the IC50 value
for MCF-7 cells was decreased from 2.610, 1.640 and
0.911 to 0.121, 0.088 and 0.054 μg/ml for 5% DMAB-
modified PLGA-TPGS nanoparticle formulations (CNP)
after 24-, 48- and 72-h incubation, respectively. As time
goes by, the 5% DMAB-modified PLGA-TPGS nanopar-
ticle formulation (CNP) showed better and better in
vitro therapeutic effects for MCF-7 cells than commer-
cial Taxotere®. This is because the accumulative drug
release was only 17.48, 22.15 and 27.98% for 5% DMAB-
modified PLGA-TPGS nanoparticle formulation (CNP)
after 24, 48 and 72 h (Figure 3), respectively, and the
release started from 0% while the Taxotere® immediately
became 100% available for the MCF-7 cells in culture.
Furthermore, the degradation of PLGA-TPGS random
copolymer may release the TPGS components, which
have synergistic anticancer activity in the presence of
anticancer agent [23,24], thus increasing cancer cell
mortality.
Conclusion
We developed three types of nanoparticle formulation
from biodegradable PLGA-TPGS random copolymer for
oral administration of anticancer drugs with docetaxel
employed as a model drug, which include 5% DMAB-
modified PLGA nanoparticles (ANP), unmodified PLGA-
TPGS nanoparticles (BNP) and 5% DMAB-modified
PLGA-TPGS nanoparticles (CNP). The design of the
nanoparticle matrix material was made to take advan-
tages of TPGS in nanoparticle preparation technology
such as high emulsification effects and high drug entrap-
ment efficiency, enhancement of therapeutic effects such
as reducing P-glycoprotein-mediated multidrug resis-
tance and superior anticancer efficacy as well as those in
drug formulation such as high cellular adhesion and
adsorption. DMAB was used to increase retention time at
the cell surface, thus increasing the chances of particle
uptake and improving oral drug bioavailability. The
results showed that the DMAB-modified PLGA-TPGS
nanoparticles have significantly higher level of the cellu-
lar uptake than that of DMAB-modified PLGA nanopar-
ticles and unmodified PLGA-TPGS nanoparticles.
Figure 6 Viability of MCF-7 cells cultured with docetaxel-
loaded 5% DMAB-modified PLGA nanoparticles (ANP),
unmodified PLGA-TPGS nanoparticles (BNP) and 5% DMAB-
modified PLGA-TPGS nanoparticles (CNP) in comparison with
that of Taxotere® at the same docetaxel dose (n = 6).
Table 3 IC50 of MCF-7 cells after 24-, 48-, 72-h incubation
with docetaxel formulated in the Taxotere®, 5%
DMAB-modified PLGA nanoparticles (ANP), unmodified
PLGA-TPGS nanoparticles (BNP) and 5% DMAB-modified
PLGA-TPGS nanoparticles (CNP)
Incubation time (h) IC50 (μg/ml)
ANP BNP CNP Taxotere®
24 1.144 1.300 0.121 2.610
48 0.926 0.590 0.088 1.640
72 0.272 0.204 0.054 0.911
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In vitro, cytotoxicity experiment showed advantages of
the DMAB-modified PLGA-TPGS nanoparticle formula-
tion over commercial Taxotere® in terms of cytotoxicity
against MCF-7 cells. In conclusion, oral chemotherapy by
DMAB-modified PLGA-TPGS nanoparticle formulation
is an attractive and promising treatment option for
patients.
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